RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE
Abstract
Press release of JSC "BAYER"
Review
For citations:
RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE. Rational Pharmacotherapy in Cardiology. 2017;13(5):729. (In Russ.)
Views:
412
Email this article 